Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Der Einfluss präoperativer Übungen und Ernährungsoptimierung auf die perioperativen Ergebnisse bei Patienten, die sich einer Behandlung wegen Rektumkarzinoms unterziehen: Die PROPEL-Studie

28. September 2026 aktualisiert von: Jeffrey A. Meyerhardt, MD, Dana-Farber Cancer Institute

The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.

The names of the groups in this research study are:

  • Group A: Prehabilitation program
  • Group B: Usual Care

Studienübersicht

Detaillierte Beschreibung

This is a non-blinded, randomized control trial to determine the feasibility of a hybrid-model, prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant therapy (chemotherapy and/or radiation) before surgical resection. Investigators hope that prehabilitation will result in improved outcomes after surgery.

Participants will be randomized into one of the study groups: Group A: prehabilitation program, or Group B: usual care. Randomization means that a participant is placed into a group by chance.

The research study procedures include screening for eligibility, in-clinic visits, physical exams, exercise training, blood tests, and questionnaires.

It is expected that about 40 participants will take part in this research study.

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Rekrutierung
        • Brigham and Women's Hospital
        • Kontakt:
        • Hauptermittler:
          • Joel Goldberg, MD
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Rekrutierung
        • Dana-Farber Cancer Institute
        • Hauptermittler:
          • Jeffrey Meyerhardt, MD
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age greater than or equal to 18 years at time of enrollment.
  • English-Speaking.
  • Diagnosis of clinical stage II-III rectal cancer.
  • Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
  • Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent.

Exclusion Criteria:

  • Distant metastatic disease known at the time of diagnosis.
  • Functional incapacity (i.e., incapable of performing exercise testing).
  • Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
  • Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
  • Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial.
  • Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Group A: Prehabilitation Program

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Virtual exercise sessions 3 days per week for 4 weeks.
  • IMN supplementation and daily multivitamin starting at 4 weeks of the preoperative phase.
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit.

A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.

Kein Eingriff: Group B: Usual Care

Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:

  • In-clinic baseline visit with assessments
  • Resection surgery per standard of care
  • In-clinic 30 day postoperative visit
  • After completion of the study period, participants will be offered exercise equipment with an exercise instruction booklet.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Enrollment Rate
Zeitfenster: Baseline

The proportion of eligible individuals that are enrolled to the study. Feasibility of the intervention is defined as an enrollment rate of greater than 10% of approached, eligible participants.

Baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Adherence Rate to the Prehabilitation Program
Zeitfenster: At post-intervention (approximately Week 4)

The number of intervention assessments completed by participants in Group A. Feasibility of the intervention is defined as at least 50% of participants adhering to at least 50% of the prescribed assessments of the prehabilitation program.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group A)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Physical Function Testing (Group B)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants.

At post-intervention (approximately Week 4)
Completion Rate of Questionnaire Assessments
Zeitfenster: At baseline and the postoperative visit (approximately Week 9)

Defined as the number of questionnaires completed by all participants.

At baseline and the postoperative visit (approximately Week 9)
Participant Fall Rate (Group A)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Participant Fall Rate (Group B)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of falls attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group A)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Hospitalization (Group B)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group A)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Rate of Musculoskeletal Injury (Group B)
Zeitfenster: At post-intervention (approximately Week 4)

Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention.

At post-intervention (approximately Week 4)
Change in Resting Blood Pressure from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Assessed by resting blood pressure. The average systolic blood pressure (of two measurements from each arm) will be recorded.

From baseline to post-operative visit (approximately week 9)
Change in Cardiorespiratory Fitness from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Assessed by VO2peak by a graded maximal (or submaximal if equipment is unavailable) cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms.

From baseline to post-operative visit (approximately week 9)
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Assessed by the Short Physical Performance Battery (SPPB) which is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support and measure in seconds. Scores are summed for the measure of balance for a range of 0 to 30 seconds; 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded. Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating highest level of performance and 0 indicating inability to complete test. A summary score ranging from 0 (worst performers) to 12 (best performers) is calculated by adding walking speed, chair stands and balance scores.

From baseline to post-operative visit (approximately week 9)
Change in Muscle Strength from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

The 1RM (repetition maximum) will be estimated from 10RM muscle strength tests on two exercises: 1) leg press, 2) chest press. 1RM values will be calculated and reported using validated equations.

From baseline to post-operative visit (approximately week 9)
Change in Height from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Height will be measured using a stadiometer, rounding up to the nearest 0.1 cm

From baseline to post-operative visit (approximately week 9)
Change in Weight from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Assessed by weight, rounding up to the nearest 0.1 kg.

From baseline to post-operative visit (approximately week 9)
Change in Waist Circumference from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Waist circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Hip Circumference from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Hip circumference will be measured, rounding up to the nearest 0.1cm.

From baseline to post-operative visit (approximately week 9)
Change in Body Mass Index from Baseline to Post-Intervention
Zeitfenster: From baseline to post-operative visit (approximately week 9)

Body composition will be assessed via bioelectrical impedance using a validated device. The device will estimate body fat using an algorithm based on participant age, sex, height, and body weight.

From baseline to post-operative visit (approximately week 9)
Change in Nutritional Status from Baseline to Post-Surgery (Group A)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Nutritional Status from Baseline to Post-Surgery (Group B)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group A)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the European Organization for Research and Treatment of Cancer's (EORTC's) Quality of Life (QOL) core questionnaire (QLQ C-30), a validated, 30-item instrument designed to quantify and measure QOL in cancer participants. Questions are rated on a four point scale from 1 "Not at all" to 4 "Very much. All items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life.

From baseline to postoperative visit, up to 9 weeks
Change in Quality of Life from Baseline to Post-Surgery (Group B)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Pittsburgh Sleep Quality Index (PSQI) Score from Baseline to Post-Surgery (Group A)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in PSQI Score from Baseline to Post-Surgery (Group B)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality.

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group A)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group B)
Zeitfenster: From baseline to postoperative visit, up to 9 weeks

Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

From baseline to postoperative visit, up to 9 weeks
Length of Hospitalization Post-Surgery (Group A)
Zeitfenster: 30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Length of Hospitalization Post-Surgery (Group B)
Zeitfenster: 30 Days

Defined as the number of days of hospitalization post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group A)
Zeitfenster: 30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Time To Return of Bowel Function Post-Surgery (Group B)
Zeitfenster: 30 Days

Defined as the number of days to a return of bowl function post-surgery.

30 Days
Discharge Disposition (Group B)
Zeitfenster: 30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days
Discharge Disposition (Group A)
Zeitfenster: 30 Days

Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics.

30 Days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Dezember 2024

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

30. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

16. August 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. August 2024

Zuerst gepostet (Tatsächlich)

21. August 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-Sharing-Zeitrahmen

Data can be shared no earlier than 1 year following the date of publication

IPD-Sharing-Zugriffskriterien

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren